Drugs / GB223
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04178044 | Nov 2018 → Dec 2020 | bone neoplasm | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178044 ↗ |
| Route | Subcutaneous | “Participants were randomly assigned to receive a single subcutaneous injection dose of 7, 21, 63, 119, or 140 mg of GB223 (n 34) or placebo (n 10)” PMID 37278972 ↗ Jun 2023 |